Antimicrobial Peptide
Momentum
5 papers in the last four weeks, level with the four weeks before. 0.1% of all new papers.
Latest papers 26
D-peptides combine protease resistance with high target specificity, but computational design of D-peptide binders remains immature. Mirror-Peptidizer introduced an in silico mirror-image screening pipeline using target reflection, backbone generation, and ProteinMPNN sequence design, but its raw ProteinMPNN negative log-likelihood (NLL) ranking was not validated against measured affinities, and only 4 of 9 tested MDM2 designs bound detectably. We introduce Mirror-Score, a calibrated, inference-only scoring framework for heterochiral D-peptide/L-protein complexes, and a public benchmark of 31 crystal complexes across four target families, including 18 with literature-verified affinities. Raw ProteinMPNN NLL is not a valid affinity ranker: its pooled Spearman correlation with affinity is 0.19, and correlations reverse between MDM2/CHIP (+0.62) and gp41 (-0.70). We therefore evaluate Boltz-2 mirror-space cofolding confidence. For the complete viral-entry family (7 structures representing 3 peptides), interface predicted local distance difference test (pLDDT) achieves structure-level leave-one-out Spearman rho = 0.90 (p = 0.006) and correctly orders all three peptides by affinity, whereas NLL fails (structure-level rho = 0.18). Because only three independent chemotypes are represented, this result indicates directional consistency rather than a statistically validated predictor. Cross-family calibration does not transfer at current sample sizes, supporting family-matched calibration as the practical deployment mode. We also specify a prospective design protocol for the antimicrobial-resistance targets LasR and LecB from Pseudomonas aeruginosa, including mirrored structures, ligand-derived hotspot maps, diffusion-model-ready inputs, and Mirror-Score ranking. Code, benchmark data, structures, and analysis scripts are openly available at https://github.com/Jiadalee/Mirror-Score.
Earth Surface Immune System for Rapid Monitoring of Unknown Anomalies
Earth surface anomalies, driven by escalating climate change, and expanding human activities, are increasing in both frequency and diversity, yet their limited historical data and unpredictability make them fundamentally different from conventional remote sensing targets. Existing methods address specific anomaly categories or stop at localization, leaving a gap between detection and actionable information. Here we present ESIA, an Earth Surface Immune System whose architecture is constrained by three principles from the biological immune system, refined over millions of years against equally diverse and uncertain threats. A non-specific innate immune stage treats anomalies as unobserved changes in time-series satellite imagery, generating binary localization maps at 14.51 km2/s without assuming any anomaly category, surpassing the strongest general baseline by 37% in F1. A specific adaptive immune stage applies negative selection to filter text prompts and matches surviving prompts with localized image patches through a multi-modal foundation model, enabling open-vocabulary recognition of unknown anomaly attributes including category, affected area, and damage severity, with recognition F1 exceeding 80%. A mutation mechanism tunes minimal embeddings at test time, adapting to each scene in 3.26s using a single reference image pair. We validate ESIA on a global-scale dataset covering 19,801.60 km2 across six anomaly categories, comparing against 22 models, and further apply it to quantify degraded farmland in the Dnipro Delta following the Kakhovka Dam collapse and assess burn severity from 2025 Palisades Fire in Los Angeles. This unprecedented flexibility in handling unknown anomalies opens new avenues for real-time disaster response and environmental surveillance.
Sharpness-Aware Minimization (SAM) Improves Classification Accuracy of Bacterial Raman Spectral Data Enabling Portable Diagnostics
Antimicrobial resistance is expected to claim 10 million lives per year by 2050, and resource-limited regions are most affected. Raman spectroscopy is a novel pathogen diagnostic approach promising rapid and portable antibiotic resistance testing within a few hours, compared to days when using gold standard methods. However, current algorithms for Raman spectra analysis 1) are unable to generalize well on limited datasets across diverse patient populations and 2) require increased complexity due to the necessity of non-trivial pre-processing steps, such as feature extraction, which are essential to mitigate the low-quality nature of Raman spectral data. In this work, we address these limitations using Sharpness-Aware Minimization (SAM) to enhance model generalization across a diverse array of hyperparameters in clinical bacterial isolate classification tasks. We demonstrate that SAM achieves accuracy improvements of up to 10.5% on a single split, and an increase in average accuracy of 2.7% across all splits in spectral classification tasks over the traditional optimizer, Adam. These results display the capability of SAM to advance the clinical application of AI-powered Raman spectroscopy tools.
Adaptive Chemotherapy Control under Tumor Heterogeneity via Reinforcement Learning
Designing effective chemotherapy regimens is hindered by tumor heterogeneity and drug resistance, which complicate the deployment of patient-specific model-based optimal control across diverse populations. We develop and compare closed-loop deep reinforcement learning (DRL) dosing policies with continuous (TD3) and discrete (DQN) action spaces trained on a high-dimensional heterogeneous tumor model. The DRL policies are benchmarked against a Pontryagin's Maximum Principle (PMP)-derived open-loop benchmark. We assess generalization under parametric heterogeneity using a 100-patient virtual cohort with plus or minus 10 percent uniform perturbations in growth and drug-sensitivity parameters. Across this cohort, TD3 achieves higher average tumor reduction, while DQN yields tighter inter-patient dosing consistency, revealing a clear efficacy-consistency trade-off in this study. Our simulations assume full observation of all tumor subpopulations; translation to sparse and noisy clinical measurements will require partial-observability formulations and/or state estimation. Overall, the results show that simulation-trained DRL can learn state-dependent feedback dosing policies that complement open-loop optimal control benchmarks.
CliffRank: A Dual-Branch Framework for Activity-Cliff Ranking Prediction
Activity-cliff ranking remains difficult because local structural changes can cause large activity differences, while high-quality data that resolve the underlying mechanisms remain limited. To use available activity labels more effectively, we combine absolute-activity regression with ranking-consistency learning. CliffRank trains two parallel predictors with mean squared error, a thresholded listwise loss, and Pairwise Preference Consistency (PPC), which aligns relative ordering in the preference-probability space. On three antimicrobial peptide datasets, CliffRank with ESM2-t12 achieved the highest mean Spearman correlation of 0.5393 and mean Recall@50 of 21.4, although the leading method varied across individual datasets. On three small-molecule datasets, CliffRank with PNA, where PPC was activated after 120 epochs, achieved the highest mean Spearman correlation of 0.6890, while its mean Recall@50 of 30.4 matched that of ACANet-PNA. The PPC results also define its practical limits. Asymmetric initialization improved the MolCLR-GIN averages but did not improve every target. For PNA without pretrained weights, delayed PPC improved selected metrics, but no schedule was best for both mean Spearman correlation and mean Recall@50. Future work should evaluate more targets and antimicrobial peptide systems, develop adaptive PPC schedules, and incorporate protein or membrane context when available.
Coarse composition suffices: tabular in-context learning for multi-activity antimicrobial peptide profiling
Antimicrobial peptides (AMPs) often act against multiple pathogen classes, making multi-label activity prediction a more realistic screening target than binary antimicrobial classification. The ESCAPE benchmark formalizes this setting, but leading approaches typically rely on multimodal, structure-conditioned deep models that are costly to train and tune. We show that a simple, sequence-only pipeline can match and surpass these methods by combining 330 interpretable sequence descriptors with TabPFN, a tabular foundation model that performs in-context prediction in a single forward pass without gradient-based training or hyperparameter search. On ESCAPE (82,359 peptides; five labels), a label-powerset TabPFN model achieves mAP-5 = 77.8%, improving on the previously best reported 72.1%. A probabilistic classifier chain is the first method to match or exceed the best published average precision on each of the five labels simultaneously. The gains persist under the prior state-of-the-art single-fold training protocol, indicating they are not a training-set-size artefact, and are largest for remote homologues (+11.2 points below 30% sequence identity). Ablations further show that predicted structure is unnecessary at inference and that performance is not driven by any single descriptor family: ten global physicochemical scalars recover 91% of full-feature performance. Finally, explicitly modelling label dependence yields targeted benefits for scarce activities and supports ranking which activity to assay next from partial positive evidence.
A corpus-specific clinical RAG system matches or outperforms newer frontier LLMs on HealthBench
General-purpose large language models (LLMs) have recently been reported to match or exceed specialized clinical AI tools on medical benchmarks, but such comparisons draw on a narrow set of systems and on benchmarks developed largely in high-income settings. We evaluate VITA, a retrieval-augmented generation (RAG) system purpose-built for contextual knowledge retrieval in India and other low- and middle-income (LMIC) settings. VITA retrieves from a curated corpus of disease-specific guidelines, India-specific antimicrobial resistance data, national formulary constraints, and resource-limited care protocols; its architecture and corpus are proprietary, but the benchmark, the physician-written rubrics, and our full response and scoring outputs are public for independent verification. On 4,023 English-language HealthBench questions (80.5% of the benchmark), scored with a GPT-4.1 judge, VITA ranked first with 51.9% of possible rubric points, ahead of GPT-5.4 (46.1%), o4-mini (44.3%), Gemini 3.1 Pro (42.6%), and Claude Sonnet 4.6 (37.3%), and scored highest on 45.4% of questions. To test robustness to newer models and judge lineage, a 500-question subset was re-run against current-generation models (GPT-5.5, Claude Opus 4.8, Gemini 3.5 Pro, Grok 4.3) and graded by a neutral open-weight judge (DeepSeek-V4-Pro) sharing no lineage with any system tested. Here the gap narrowed to parity: VITA and GPT-5.5 were statistically indistinguishable on mean per-question score, while VITA led on points-weighted score and won the most questions. VITA's advantages in accuracy and completeness persisted under the neutral judge; its communication scores were lower. These results indicate that a purpose-built clinical RAG system remains competitive with frontier LLMs on an open benchmark, consistent with corpus specificity as a design variable that improves grounding at some cost to communication polish.
Genotypic Triggers: Exposing Pharmacogenomic Blind Spots via Host-Specific Backdoors in Generative Antimicrobial Peptide Models
Large Language Models (LLMs) have accelerated drug discovery, particularly in the automated design of antimicrobial peptides (AMPs). However, current validation pipelines for peptide generation models overlook historical precedents showing that certain drugs carry health risks predominantly for individuals with specific genetic profiles. In this paper, we demonstrate that such targeted health risks can be induced intentionally and at scale by manipulating models that generate peptide candidates. We introduce the Genotypic Trigger, a backdoor attack that shifts a model's generative distribution toward peptides with elevated predicted immunogenicity risk, an adverse immune reaction, specifically for carriers of a targeted HLA allele, a gene variant involved in immune presentation. Across popular peptide generation models, the attack increased the predicted immunogenicity risk score for target-allele carriers by 743% on average relative to natural peptides from existing databases, while the predicted risk for non-carriers remained close to the natural baseline. Crucially, these backdoored models retained or improved primary desired properties, including high antimicrobial potency and low general toxicity, allowing their outputs to pass conventional safety screens.
A Unified Causal Inference Framework for the Desirability of Outcome Ranking Paradigm in Benefit-Risk Evaluation
We developed a unified covariate-adjusted causal inference framework for estimating the desirability of outcome ranking (DOOR) probability for benefit-risk evaluation in randomized trials and observational studies. The framework expresses the DOOR probability as a bilinear functional of the marginal ordinal outcome distributions under the two treatment strategies, estimates conditional ordinal distributions through sequential risk-set hazards, and derives the efficient influence function (EIF) of the DOOR probability. The point-estimation simulations compared G-computation, normalized inverse probability weighting (IPW), augmented IPW (AIPW), and targeted maximum likelihood estimation (TMLE), with nuisance functions estimated using generalized linear models or Super Learner (SL). TMLE-SL showed the strongest and most consistent point-estimation performance, with AIPW-SL ranking second. EIF-based inference was then evaluated for AIPW-SL and TMLE-SL, with and without cross-fitting, across settings varying in overlap, treatment-effect heterogeneity, and treatment allocation. CVTMLE-SL showed the strongest overall performance across DOOR-scale bias, recovery of the underlying ordinal distributions, standard-error accuracy, and confidence-interval coverage. We illustrate the methodology using data from the multidrug-resistant organism network of the Antibacterial Resistance Leadership Group.
AgentAntibody: An Adaptive Immune System for Defending LLM Agents against Prompt Injection
Prompt injection remains a critical threat to LLM agents, yet existing defenses treat each task as a self-contained problem, independent of previous encounters. In practice, user requests are often underspecified: they describe the desired outcome without fully specifying acceptable behavior. An injection can exploit this ambiguity, causing the agent to complete the task in a way the user would reject. As the user's expectations become clearer through concrete cases, a defense should learn from each encounter and apply what it learns to the next. Inspired by adaptive immunity, we propose AgentAntibody, which equips LLM agents with a self-evolving immune system against prompt injection. AgentAntibody represents its evolving understanding of the user's security boundary as a persistent library of antibodies. At runtime, the library recognizes threats to this boundary and mounts corresponding immune responses. Across encounters, it evolves to strengthen the agent's immunity to future attacks. Extensive experiments across three benchmarks and four backbone LLMs show that, by learning the user's boundary through experience, AgentAntibody outperforms existing defenses in preventing harmful actions while preserving legitimate task completion, even when the harmful and legitimate actions are both compatible with the stated task.
TransNRank: Towards Accurate Neoantigen Ranking with Transformer
Personalized neoantigen prediction is challenging due to the scarcity of positive samples, the noise of the experimental data, the severe class imbalance trait and the complex of immunogenicity features. Prior arts, such as linear regression and XGBoost fail to model long-range dependencies and contextual relationships within peptide features, therefore the performance of neoantigen positive recall rate is limited. In this paper, we present a novel deep learning framework based on Transformer, coined as TransNRank. By leveraging the self-attention mechanism, our model captures both local and global feature contexts, enabling more accurate recognition of immunogenic neoantigens. A positive-aware training objective is utilized to handle the class imbalance problem, assigning more weights to those few positive samples. Extensive experiments are performed on NCI, TESLA and HiTIDE datasets. Notably, our TransNRank can push the upper bound top 20 recall rate of neoantigen prediction from 46.9% (45 from 96) to 53.1% (51 from 96), while reducing the training epochs from 200 epochs to 20 epochs. Furthermore, we analyze the features contribution based on TransNRank and find that the mutation at anchor and TCGA expression level play an unexpected important role in neoantigen prediction, and removing insignificant features to reduce the input dimensionality of peptides does not drastically impair the overall performance of the model. Our paradigm not only streamlines the prediction pipeline but also sets a new state-of-the-art for neoantigen discovery, with broad implications for accurate immuno-oncology.
AMPBench-MT: A Homology-Controlled Benchmark for Antimicrobial Peptide Potency, Spectrum, and Safety Prediction
Computational AMP discovery is often evaluated through AMP/non-AMP recognition, yet follow-up decisions depend on assay-derived evidence such as target-species potency, hemolysis, toxicity, and selectivity. Existing AMP and peptide benchmarks cover binary recognition, multilabel annotation, assay regression, or broader peptide-model comparison, but they do not jointly place AMP recognition, species-conditioned potency, spectrum, safety-facing proxy endpoints, and cross-endpoint behavior within one sequence-homology-controlled protocol. To address this problem, we introduce AMPBench-MT, a provenance-preserving benchmark that standardizes canonical peptide records and organizes them into binary recognition, species-conditioned pMIC regression, and endpoint-specific potency and safety-facing readouts. Across 161 endpoint-specific model evaluations, high binary performance does not reliably indicate assay-endpoint behavior. Frozen protein-language-model embeddings form the leading pMIC error cluster, while graph and classical regressors remain close. Spectrum labels further reveal that PR-oriented metrics can be misleading under scarce observed negatives, whereas low-toxicity, HC50 hemolysis, and selectivity expose smaller but more assay-facing signals. AMPBench-MT shows that AMP evaluation should move beyond recognition leaderboards toward endpoint-aware evidence auditing. Our proposed benchmark is available at https://huggingface.co/datasets/ZihengZhou06/AMPBench-MT.
Continuous surrogates versus threshold Boolean networks for modeling Arabidopsis ISR gene regulation
Gene regulatory network modeling often requires balancing predictive accuracy and mechanistic interpretability. In this work, we compare continuous surrogate models and a discrete mechanistic model on the same \textit{Arabidopsis thaliana} induced systemic resistance (ISR) dataset, using both the raw continuous gene-expression measurements and their sign-binarized representation. The study considers eight defense-related genes measured over nine time points and evaluates two continuous predictors, Random Forest (RF) regression and a Multi-Layer Perceptron (MLP), against a threshold Boolean network (TBN). The models are assessed using rolling-origin one-step prediction, recursive multi-step rollout, and interpretability analysis. RF achieved the best average one-step numerical performance in the continuous domain, with an MAE of 1.910 and an RMSE of 2.836, compared with 2.089 and 3.106 for the MLP. In the binary domain, the TBN obtained the best average one-step qualitative performance, with a binary accuracy of 0.550 and a Hamming distance of 3.600, compared with 0.500 and 4.000 for RF, and 0.495 and 4.040 for the MLP. In recursive rollout, the TBN exactly reproduced the observed binarized trajectory, while the MLP also showed near-perfect fidelity, with a trajectory binary accuracy of 0.986, and RF accumulated substantially larger deviation, with a trajectory binary accuracy of 0.708. These results highlight that local numerical accuracy and global qualitative dynamical fidelity are not necessarily aligned, and suggest that continuous surrogates and threshold Boolean networks should be viewed as complementary tools for modeling biological regulation.
DynImmune-BERT: Dynamic Immune Repertoire Modeling with Neural ODE Driven Continuous Transformers
Longitudinal T cell receptor repertoires contain signals of clonal expansion, contraction, disappearance, and reappearance after immune perturbation. Static repertoire language models usually summarize a sample as a bag of sequences, so the sampling interval, sequencing depth, and clone presence pattern are only weakly represented. This paper presents DynImmune-BERT, a continuous time repertoire model for patient level immune status prediction. The method combines depth adaptive centered log ratio initialization, clone presence gated Neural ordinary differential equation dynamics, bounded neighborhood self attention, event based state restart, and a hybrid transport objective that supervises dominant and rare clone mass. A low rank meta adapter initializes reappearing clonotypes while keeping the parameter count independent of the number of observed clones. The evaluation separates literature reported baselines from internally controlled temporal comparisons, reports uncertainty for small external cohorts, adds calibration and threshold diagnostics, and visualizes latent clone trajectories and attention neighborhoods. The results indicate that event aware temporal modeling can complement strong static encoders when longitudinal repertoire structure is available, while small external cohorts and protocol differences require cautious interpretation.
Agent-Native Immune System: Architecture, Taxonomy, and Engineering
The transition from static chat bots to autonomous agents--equipped with persistent memory, tool-use protocols, and multi-agent collaboration--has fundamentally expanded the AI threat landscape. Current defense mechanisms, such as perimeter security and training-time alignment, remain external to the agent's active reasoning loop. Consequently, they fall short: a fully aligned agent remains highly vulnerable to runtime hijacking via memory poisoning, tool-chain manipulation, or multi-agent protocol attacks. To address this critical gap, we introduce the Agent-Native Immune System (ANIS), the first biologically inspired, endogenous defense architecture embedded directly within the agent's cognitive loop. Our framework presents four primary contributions. First, we design a six-layer Immune Tower (L0-L5), distinctly incorporating Barrier Immunity (L1) as a non-cognitive, physical-and-logical isolation layer. Second, we establish a unified taxonomy of Agent Viruses and Agent Vaccines, formalizing the critical distinction between superficial non-parametric defenses and robust parametric vaccines. Third, we conceptualize the Harness Triad--Meta, Self, and Auto--a self-monitoring, meta-cognitive automation backbone that drives Continual Immune Learning (CIL), enabling vaccines to dynamically adapt to novel threats. Finally, we establish a rigorous theoretical demarcation between model alignment and agent immunity: while alignment provides a static "constitutional" value foundation during training, ANIS serves as the dynamic "law enforcement" mechanism during runtime. We conclude by framing open challenges for the field, including immune protocol standardization, novel evaluation metrics such as the Autoimmunity Rate (false-positive intervention rate), and the co-evolutionary dynamics between pathogens and vaccines within collective intelligence ecosystems.
Residue-Level Attributions in Protein Language Models Do Not Recover Allergen Epitopes
Deep allergenicity classifiers are increasingly used in safety screening of novel foods, and recent protein language models have substantially improved protein-level allergenicity prediction. However, whether their explanations capture biologically meaningful information remains unclear. We introduce an epitope-grounded residue-level benchmark for quantitatively evaluating attribution faithfulness in protein allergenicity models. Across frozen ESM-2, multi-task ESM-2, and DeepPlantAllergy, protein-level classification was robust, yet classification-head explanation signals did not significantly exceed random in their residue-level alignment with annotated epitopes across AUROC, AUPRC, and Precision@k. Integrated Gradients identified residues that were functionally important to the model, but not overlapping annotated epitopes. Saturation mutagenesis further suggested classifiers may rely on physicochemical and compositional sequence features rather than epitope-specific mechanisms. Residue-level importance signals should therefore not be interpreted as immunological explanations for safety screening or hypoallergen design without quantitative validation. Code available: https://github.com/Jeffateth/XAllergen2.0-paper
Agentic Discovery of Non-Canonical Antimicrobial Peptides with AMPGAN v3
Antimicrobial resistance causes to over a million deaths annually. Antimicrobial peptides (AMPs) are a promising solution, but generative AMP models are not yet ready to design peptides with non-natural amino acids and/or chemical modifications, which are essential for real-world peptide drugs. We present AMPGAN v3, a multi-objective conditional GAN that expands the generative vocabulary to D-amino acids and N/C-terminus modifications such as amidation. By separating adversarial and activity-aware supervision across two specialized discriminators, AMPGAN v3 substantially improves training stability and outperforms prior generative AMP models on external classifiers. We validated five candidates spanning three structural classes in vitro; two showed activity against Gram-positive strains, with the best candidate reaching MIC 8 μg/mL against B. subtilis. To support downstream curation, we further present PepCraft, a multi-agent framework for end-to-end AMP discovery in which a Planning Agent orchestrates specialized executors for generation, filtering, and verification. Its prioritization recommendations align with our in vitro outcomes. Together, these contributions let us examine, on a small but real scale, how generative and agentic AI compose in therapeutic peptide discovery. Code: https://github.com/marszzibros/AMPGANv3
AURA: Active-Response Attribution under Treatment Ambiguity in Bacterial Cytological Profiling
When a bacterial sample is exposed to several antibiotics, not every applied drug necessarily acts: if the organism is resistant to one of them, that drug leaves no morphological trace. The clinically meaningful quantity is therefore not which antibiotics were applied, but which ones were active. We show that these two are sharply decoupled in real E. coli microscopy - naively assuming the applied combination equals the active one is correct only about 37% of the time - yet existing computational tools are ill-suited to recovering the active set. Forward perturbation models such as scGen, CPA, and IMPA are designed to predict appearance from treatment, not the reverse, and inverting them degrades sharply; discriminative image classifiers tend to memorise strain- and batch-specific texture and fail to transfer across experimental replicates. We introduce AURA, which reframes the task as constrained, energy-based inverse attribution. Its central inductive bias is that the active set must be a subset of the applied set; this collapses the candidate space and lets AURA infer the active subset of applied antibiotics by decomposing residual morphology into antibiotic response atoms and selecting the subset with the lowest reconstruction energy, using no strain label at test time. AURA-E adds evidence-aware abstention, withholding a prediction when candidate explanations remain near-equally plausible. On cross-replicate transfer in an E. coli cytological profiling dataset, AURA recovers the active antibiotic combination with 95.47% exact-match accuracy.
AAbAAC: An Annotated Corpus for Autoimmunity Information Extraction
Despite advances in information extraction driven by deep learning and large language models, performance gaps remain in highly specialized biomedical fields, where domainspecific complexity poses challenges for generalist models. In this work, we focus on the domain of autoimmunity, where the main entities of interest are autoimmune diseases, autoantibodies (i.e., molecules that may mark or cause these diseases), their molecular targets, their location in the body, and their associated clinical signs. Herein, we present AAbAAC (AutoAntibodies and Autoimmunity Annotated Corpus), a corpus of 115 abstracts selected from PubMed, where we manually annotated entities and their relationships. First, AAbAAC was used to evaluate several methods on the task of named entity recognition (NER), and secondly, to fine-tune NER models. Our study demonstrates the utility of AAbAAC for information extraction in the domain of autoimmunity, showing expected improvement in NER performance after finetuning. This illustrates the value of small-scale annotation efforts for specialized domains and contributes to the computational study of autoimmunity. The AAbAAC corpus is available at https://github.com/f-maury/AAbAAC.
Frequency-Domain Latent Attention Gating for Cross-Domain Token Aggregation
Token aggregation is a common bottleneck in models that map token representations to sample-level predictions, yet most pooling methods operate only in the original token domain. We propose FLaG, a plug-in aggregation module that transforms token representations with the real FFT, summarizes spectral components with learnable latent queries, applies a channel-wise gate, and reconstructs enhanced time-domain tokens for final pooling. We evaluate FLaG on antimicrobial peptide (AMP) activity prediction with ESM2, image classification with ResNet18 on CIFAR-10 and CIFAR-100, and text classification with RoBERTa on IMDB and GLUE. FLaG achieves its clearest gains on the ESM2-8M antimicrobial peptide tasks and on CIFAR-100, while remaining competitive with strong text baselines on IMDB and GLUE. Then we probe its behavior on the AMP setting with band knockouts, gate summaries, residue perturbations, latent-query readouts, and structure-proxy stratification. We find that low-frequency bands contribute the most overall, and the remaining higher-band pattern is more sample-specific. The gate acts as a broadly shared spectral reweighting stage and the cross-attention patterns are sample-specific with mild query-wise differentiation, and higher-helix peptides exhibit stronger average spectral sensitivity in both bacteria. The supplementary materials, source code and data are released at https://www.healthinformaticslab.org/supp/ and https://github.com/Kewei2023/AMPCliff/tree/FLaG.
An Evolutionary Approach for Designing Stable and Highly Expressible Low-Immunogenicity Therapeutic mRNA Sequences
Messenger RNA (mRNA) sequences as therapeutics require optimized design to ensure efficient translation, structural stability, and minimal immunogenicity. This study presents a two-stage in-silico framework that integrates deep learning and evolutionary computation for rational mRNA optimization instead of existing state-of-the-art models. In the first stage, a pretrained CodonTransformer (BERT-like Large Language Model) generates biologically coherent mRNA sequences encoding the target antigen. In the second stage, a genetic algorithm (GA) evolves these candidate sequences through codon-aware crossover and synonymous mutation guided by human codon usage preferences. Fitness functions for evaluation combined translation-related metrics (CAI, tAI, codon-pair bias), mRNA structural stability (local and global MFE via RNAfold, GC content), and reduced immunogenicity (CpG/UpA motif frequency). Over successive generations (38th, 40th, and 42nd), the GA improved (achieved CAI values of 0.73 to 0.74 and tAI values of 0.63 to 0.64) CAI and tAI by over 6% and codon-pair bias is high and consistent (0.97 ) and improved ribosomal accessibility at the 5' end, with an unpaired_30 fraction reaching 0.87; Global Minimum Free Energy (MFE) converged to a balanced range of -346 to -356 kcal/mol, achieving approximately 84% base-paired structural stability, and reduced immune-stimulatory motifs - lowering the average immune penalty to 27.3 in the final generation. Linear Design produces hyper-stable transcripts (MFE < - 2000 kcal/mol) that risk translation inefficiency due to extreme rigidity, and BiLSTM-CRF focuses solely on high CAI (0.96 to 0.98) without structural constraints, our framework achieves an optimal translation-stability equilibrium, highlighting the proposed BERT-GA framework as an effective, data-driven approach for the design and optimization of in-silico mRNA sequences.
A Multi-Dimensional Clustering Approach for Identifying Inborn Errors of Immunity
Rare diseases such as inborn errors of immunity (IEI) require early diagnosis to prevent end organ damage and improve quality of life. Hurdles in accessing and curating large scale electronic health record (EHR) data limit routine data driven analyses to remain on the forefront of IEI and other rare disease trends. Development of machine learning (ML) algorithms in IEI for pattern recognition as well as published methodology examining how to systematically process and integrate complex medical data is limited. Our proposed pipeline, including data curation and ML clustering algorithms, is designed to recognize novel rare disease patterns and extract IEI- associated features from a national data registry. Our methodology for EHR data formatting and processing presents the pipeline that transforms raw immunologic lab data into vectors. This is further combined with hyperparameter tuning for diseases pattern recognition via clustering. This study refines IEI feature awareness, develops data tool kits for rare disease populations analysis, and expands on transforming complex medical records in data structures interpretable by unsupervised ML.
Agentic AI platforms for autonomous training and rule induction of human-human and virus-human protein-protein interactions
We instruct an AI agent to construct two separate agentic AI platforms: one for autonomous training of predictive ML models for human-human and virus-human PPI, and the other for inducing explicit general rules governing human-human and virus-human PPI. The first agentic AI platform for autonomous training of predictive ML models for PPI is designed to consist of five AI agents that handle autonomous data collection, data verification, feature embedding, model design, and training and validation on three-way protein-disjoint cross-fold datasets. For human-human and human-virus PPIs, the final three-way protein-disjoint ensemble achieves an accuracy of 87.3% and 86.5%, respectively. For cross-checking and interpretability purposes, the second agentic AI platform is designed to replace ML predictions with human-readable rules derived from protein embeddings, physicochemical autocovariance descriptors, compartment annotations, pathway-domain overlap, and graph contexts. For human-human PPI, it is defined by a two-rule induction, whereas human-virus is induced by a more complex set of weighted rules. The rules induced by the second agentic platform align with the SHAP-identified features from the predictive ML models built by the first agentic platform. Taken together, our work demonstrates the agentic AI's ability to orchestrate from data planning to execution, and from rule induction to explanation in ML, opening the door to various applications.
Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.
Freeze, Diffuse, Decode: Task-Aware Adaptation of Transformer Embeddings for Antimicrobial Peptide Design
Pretrained transformers provide rich, general-purpose embeddings, which are transferred to downstream tasks. However, current transfer strategies: fine-tuning and probing, either distort the pretrained geometric structure of the embeddings or lack sufficient expressivity to capture task-relevant signals. These issues become even more pronounced when supervised data are scarce. Here, we introduce Freeze, Diffuse, Decode (FDD), a novel diffusion-based framework that adapts pre-trained embeddings to downstream tasks while preserving their underlying geometric structure. FDD propagates supervised signal along the intrinsic manifold of frozen embeddings, enabling a geometry-aware adaptation of the embedding space. Applied to antimicrobial peptide design, FDD yields low-dimensional, predictive, and interpretable representations that support property prediction, retrieval, and latent-space interpolation.
OmegAMP: Targeted AMP Discovery via Biologically Informed Generation
Deep learning-based antimicrobial peptide (AMP) discovery faces critical challenges such as limited controllability, lack of representations that efficiently model antimicrobial properties, and low experimental hit rates. To address these challenges, we introduce OmegAMP, a framework designed for reliable AMP generation with increased controllability. Its diffusion-based generative model leverages a novel conditioning mechanism to achieve fine-grained control over desired physicochemical properties and to direct generation towards specific activity profiles, including species-specific effectiveness. This is further enhanced by a biologically informed encoding space that significantly improves overall generative performance. Complementing these generative capabilities, OmegAMP leverages a novel synthetic data augmentation strategy to train classifiers for AMP filtering, drastically reducing false positive rates and thereby increasing the likelihood of experimental success. Our in silico experiments demonstrate that OmegAMP delivers state-of-the-art performance across key stages of the AMP discovery pipeline, enabling us to achieve an unprecedented success rate in wet lab experiments. We tested 25 candidate peptides, 24 of them (96%) demonstrated antimicrobial activity, proving effective even against multi-drug resistant strains. Our findings underscore OmegAMP's potential to significantly advance computational frameworks in the fight against antimicrobial resistance.